The IGHMBP2 Knockout A-549 Polyclonal Cells are a CRISPR/Cas9-edited polyclonal population of A-549 cells with targeted disruption of the IGHMBP2 gene. This heterogeneous knockout model provides a mixed genetic background for robust functional studies, avoiding clonal bias. IGHMBP2 encodes an ATP-dependent RNA helicase essential for RNA metabolism and motor neuron survival, and its loss is linked to neuromuscular diseases.
The A-549 cell line was derived from a 58-year-old male lung adenocarcinoma and serves as a widely used model for non-small cell lung cancer (NSCLC). These epithelial cells harbor a KRAS G12S mutation and retain tumor-relevant signaling pathways, making them suitable for oncogenic studies and therapeutic testing. Their amenability to genetic editing and functional assays renders them an optimal host for the IGHMBP2 knockout model.
IGHMBP2 functions as an ATP-dependent RNA/DNA helicase that interacts with the SMN complex, including Gemin2, and associates with RNA polymerase II and the exon junction complex. It regulates nonsense-mediated mRNA decay and translational initiation by binding to ribosomal RNA and translation initiation complexes, downstream of cellular stress signals. Through these interactions, IGHMBP2 controls the expression of targets such as immunoglobulin heavy chain genes and is critical for motor neuron survival. Its deficiency disrupts RNA surveillance and translation, leading to DSMA1 and CMT2S pathologies.
In the lung adenocarcinoma context, IGHMBP2 knockout allows investigation of RNA metabolism’s role in tumor biology. IGHMBP2??s involvement in RNA processing and translation may influence cancer cell proliferation, apoptosis, and drug response. This polyclonal population captures the phenotypic heterogeneity of NSCLC, enabling the study of bulk cellular behaviors relevant to lung cancer progression and therapeutic vulnerability, without clonal selection artifacts.
Researchers can utilize these cells for Western blotting, RT-qPCR, RNA-seq, immunofluorescence, cell proliferation, apoptosis, and migration/invasion assays. The model supports transcriptome-wide analyses of RNA processing and drug sensitivity profiling for lung cancer or motor neuron disease targets. For additional information, please contact Ascent Research.
